The Global Attention Deficit Hyperactivity Disorder Market is Predict to reach $16.9 Billion by 2028, at a CAGR of 4%

Published Date: 30-Nov-2022

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Attention Deficit Hyperactivity Disorder Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Attention Deficit Hyperactivity Disorder Market size is expected to reach $16.9 billion by 2028, rising at a market growth of 4.0% CAGR during the forecast period.

The Non-stimulants market is experiencing a CAGR of 6.1% during (2022 - 2028). The recent approval of multiple non-stimulant-based drug therapies is the main factor driving the growth of the segment. These innovations have broadened the accessibility of treatment even to those who couldn’t take stimulant drugs for various reasons. In addition, non-stimulant medicines are also prescribed when other medications have detrimental side effects.

The Adults market is leading the Global Attention Deficit Hyperactivity Disorder Market by Demographics in 2021; thereby, achieving a market value of $10 billion by 2028. Adults over 18 who have ADHD struggle to function in social and professional settings as well as in the classroom. Adults having ADHD may struggle to prioritize and concentrate, which can result in missed deadlines, canceled meetings, and neglected social activities. In addition, the inability to restrain impulses can cause a variety of behaviors, such as impatience while driving in line or traffic, mood swings, and angry outbursts.

The Hospital Pharmacy market is anticipated to witness a CAGR of 5.7% during (2022 - 2028). Hospital pharmacists are knowledgeable about medications and may help individuals with ADHD and their caregivers or parents in choosing the proper remedy. Furthermore, the increasing availability of various treatment alternatives and the introduction of new therapeutic medications for better and more effective treatment with fewer side effects have raised the number of patients opting for treatments in hospitals.

The North America market dominated the Global Attention Deficit Hyperactivity Disorder Market by Region in 2021; thereby, achieving a market value of $9.7 billion by 2028. The Europe market is poised to grow a CAGR of 4.3% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 5.6% during (2022 - 2028).

Full Report:

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Eli Lilly And Company, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Johnson & Johnson (Johnson & Johnson Services, Inc.), Lupin Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Mallinckrodt PLC, Purdue Pharma L.P., Aytu BioPharma, Inc. and Supernus Pharmaceuticals, Inc.

Global Attention Deficit Hyperactivity Disorder Market Segmentation

By Drug Type

  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Lisdexamfetamine
    • Dexmethylphenidate
  • Non-stimulants
    • Atomoxetine
    • Guanfacine
    • Clonidine
    • Others

By Demographics

  • Adults
  • Children

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Eli Lilly And Company
  • Pfizer, Inc. (Global Blood Therapeutics, Inc.)
  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • Lupin Limited
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Mallinckrodt PLC
  • Purdue Pharma L.P.
  • Aytu BioPharma, Inc.
  • Supernus Pharmaceuticals, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

North America Attention Deficit Hyperactivity Disorder Market Future Scope & Opportunities 2022-2028

Europe Attention Deficit Hyperactivity Disorder Market Size & Growth Forecast 2022-2028

Asia Pacific Attention Deficit Hyperactivity Disorder Market Size, Share & Industry Outlook to 2028

LAMEA Attention Deficit Hyperactivity Disorder Market Growth, Trends & Forecasts 2022-2028

Request a Free Sample Copy

Why Choose Us

  • 24/7 Research support
    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Information security
    Your personal and confidential information is safe and secure.